| Property | Terbinafine | Flucytosine | Griseofulvin |
|---|---|---|---|
| Route | Oral or topical | Oral (IV available) | Oral only |
| Key toxicity | Hepatotoxicity (rare); taste disturbance; GI effects | Bone marrow suppression; GI effects — concentration-dependent | Headache; GI effects; photosensitivity; teratogenic |
| Drug interaction | Inhibits CYP2D6 — check tricyclics, beta-blockers, antiarrhythmics | Accumulates in renal failure; amphotericin B worsens renal function → monitor levels | Induces CYP3A4 — reduces warfarin, oral contraceptives, cyclosporine |
| Monitoring | Liver function tests for prolonged courses | TDM (peak 50–100 mg/L); CBC twice weekly; renal function | None routine; counsel on alcohol (disulfiram-like reaction) |
| Special caution | Avoid in severe hepatic impairment | Never use as monotherapy — resistance in days | Avoid in pregnancy (teratogenic); take with fatty food |
Terbinafine: drug of choice for dermatophyte onychomycosis and tinea capitis from Trichophyton tonsurans. Flucytosine: use only in combination with amphotericin B for cryptococcal meningitis induction — never alone. Griseofulvin: tinea capitis in children, especially Microsporum canis where terbinafine is less effective. Outside these niches, none of the three agents offers advantages over the polyenes, azoles, or echinocandins for invasive fungal disease.